+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Evidence of genetic factors in hidradenitis suppurativa

British Journal of Dermatology 113(1): 1-8
Evidence of genetic factors in hidradenitis suppurativa
Probands [26] suffering from hidradenitis suppurativa were identified. Investigation of their families eventually confirmed a total of 62 affected individuals from 23 families. In 11 families there was evidence in favor of single gene or Mendelian inheritance; in another 3 there was familial occurrence; in 9 families there was a negative family history at the time of enquiry. The disease appears to be commoner than reports suggest and it is probable that there is an underestimation of affected individuals in the community. Problems of identification including variable age of onset and psycho-social factors were found and may be responsible for false-negative family histories.

Accession: 005411431

PMID: 4015966

DOI: 10.1111/j.1365-2133.1985.tb02037.x

Download PDF Full Text: Evidence of genetic factors in hidradenitis suppurativa

Related references

Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. Reviews in Endocrine & Metabolic Disorders (): -, 2016

Definition of Moderate to Severe Hidradenitis Suppurativa: A Position Paper by the Canadian Hidradenitis Suppurativa Foundation (CHSF). Journal of Cutaneous Medicine and Surgery 20(6): 613-615, 2016

Hidradenitis suppurativa complicating naevus comedonicus: the possible influence of mechanical stress on the development of hidradenitis suppurativa. Dermatology 220(4): 323-325, 2010

HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. Journal of the European Academy of Dermatology and Venereology 30(6): 989-994, 2015

Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. British Journal of Dermatology 171(6): 1434-1442, 2015

Hidradenitis suppurativa: a disease of the absent sebaceous gland? Sebaceous gland number and volume are significantly reduced in uninvolved hair follicles from patients with hidradenitis suppurativa. British Journal of Dermatology 164(5): 1017-1022, 2011

Pharmacologic interventions for hidradenitis suppurativa: what does the evidence say?. American Journal of Clinical Dermatology 13(5): 283-291, 2013

Hidradenitis suppurativa: evidence for an endocrine abnormality. British Journal of Surgery 72(12): 1002-1004, 1985

Medical Treatments of Hidradenitis Suppurativa: More Options, Less Evidence. Dermatologic Clinics 34(1): 91-96, 2016

Hidradenitis suppurativa and associated factors: still unsolved problems. Journal of the American Academy of Dermatology 61(2): 362-365, 2009